ArticleAntimicrobial agents and chemotherapy2018
Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Discovery of potent DprE1-targeted antitubercular agents: synthesis and evaluation of PBTZ169/TBA7371-based derivatives.Molecular diversity · 2026Article
- Mechanism of the M. tuberculosis DprE1-DprE2 epimerase complex and inhibition by anti-tubercular drugs.Nature chemical biology · 2026Article
- Design, synthesis and antitubercular evaluation of novel 5,6-diphenyl-1,2,4-triazine-piperazine derivatives targeting mycobacterial dihydrofolate reductase.ADMET & DMPK · 2026Article
- The progress ofFrontiers in medicine · 2024Review
- Pharmacophore mapping, 3D QSAR, molecular docking, and ADME prediction studies of novel Benzothiazinone derivatives.In silico pharmacology · 2024Article
- Synthesis and Structure-Activity Relationships of a New Class of Oxadiazoles Targeting DprE1 as Antitubercular Agents.ACS medicinal chemistry letters · 2023Article
- Side Chain-Modified Benzothiazinone Derivatives with Anti-Mycobacterial Activity.Biomedicines · 2023Article
- Assay development and inhibition of theMicrobiology (Reading, England) · 2023Article
- Recent Advances of DprE1 Inhibitors againstACS omega · 2022Review
- OvercomingActa pharmaceutica Sinica. B · 2022Review
- Identification of Mutations Associated With Macozinone-Resistant in Mycobacterium Tuberculosis.Current microbiology · 2022Article
- Synthesis and evaluation of triazole congeners of nitro-benzothiazinones potentially active against drug resistantRSC medicinal chemistry · 2022Article
- Development of 6-Methanesulfonyl-8-nitrobenzothiazinone Based Antitubercular Agents.ACS medicinal chemistry letters · 2022Article
- Machine Learning Models forMolecular pharmaceutics · 2022Article
- Design and characterisation of piperazine-benzofuran integrated dinitrobenzenesulfonamide asJournal of enzyme inhibition and medicinal chemistry · 2021Article
- Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment.Pharmaceutics · 2021Review
- Synthesis and Biological Evaluation of Novel Benzhydrylpiperazine-Coupled Nitrobenzenesulfonamide Hybrids.ACS omega · 2021Article
- Hydride-induced Meisenheimer complex formation reflects activity of nitro aromatic anti-tuberculosis compounds.RSC medicinal chemistry · 2021Article
- 8-cyanobenzothiazinone analogs with potent antitubercular activity.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2021Article
- A Novel Sulfonyl-Based Small Molecule Exhibiting Anti-cancer Properties.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macozinone (MCZ) is a tuberculosis (TB) drug candidate that specifically targets the essential flavoenzyme DprE1, thereby blocking synthesis of the cell wall precursor decaprenyl phosphoarabinose (DPA) and provoking lysis of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.